Spitalul Clinic De Pneumoftiziologie Leon Daniello
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At Spitalul Clinic De Pneumoftiziologie Leon Daniello in Cluj Napoca, clinical research in respiratory tract diseases focuses on major chronic conditions that affect breathing and lung function. The studies explore new and existing therapies for asthma, chronic obstructive pulmonary disease, bronchiectasis, and idiopathic pulmonary fibrosis, with the aim of improving symptom control, reducing flare-ups, and supporting better long-term outcomes.
- Testing new treatment options for asthma, including mild, moderate, and uncontrolled forms
- Evaluating therapies for chronic obstructive pulmonary disease to reduce exacerbations and improve lung function
- Studying care approaches for bronchiectasis and idiopathic pulmonary fibrosis
This department is active in research aimed at making respiratory care more effective, especially for patients living with persistent or progressive lung disease.
Immune System Phenomena
Research in immune system phenomena at this site examines how inflammation contributes to airway and lung disease. Many of the trials target immune-driven forms of asthma and COPD, with a broader interest in reducing exacerbations and improving disease control through better treatment strategies.
- Investigating biologic and anti-inflammatory therapies for moderate-to-severe asthma
- Assessing immune-targeted treatments for chronic obstructive pulmonary disease and frequent exacerbations
- Exploring treatments for pulmonary hypertension associated with interstitial lung disease
The work at Sectia Clinica Pneumologie I reflects a strong interest in precision approaches that address inflammation as a key driver of respiratory illness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Chiesi Farmaceutici S.p.A.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.7trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic De Pneumoftiziologie Leon Daniello
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 5 | Unknown | 2022-04-22 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.